Follow Michael A RobinsonStart the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
There's tremendous momentum in the legal cannabis sector right now. The boom is crackling with excitement and flush with money, reminiscent of the old California Gold Rush.
Call this the "green rush," where weed investors are pulling in profits hand over fist.
Last month, for instance, it was reported that the 50 licensed marijuana retailers in Nevada, which only went "fully legal" on July 1, are already running out of marijuana to sell.
And California is less than six months from opening a legal, recreational market that will dwarf all other legal weed states, plus the entire nation of Canada. I'll tell you why I'm expecting monster profits there in a minute.
But… one of my favorite legal weed plays has been in the news lately for an entirely different reason.
Now, it's not a grower, and it's not a retailer (I save those recommendations for my paid-up Nova-X Report subscribers as part of a comprehensive, well-balanced, 30-stock weed portfolio), but it will be one of the biggest, most important players in this boom sector, especially when California lifts the curtain on its market.
And I couldn't be happier with the price we're getting here…
The "Green Rush" Is Very Real
Comparing the legal cannabis sector to the legendary 1850s California Gold Rush might seem like hyperbole, but it's no idle boast.
Sure, plenty of forty-niners struck it rich, but the real fortunes went to the folks who sold the prospectors the things – tools, clothes, food, housing – they needed to chase their dreams of gold riches.
In fact, this is where we get the term "pick-and-shovel play" from.
Levi Strauss is a famous example. The Bavarian immigrant didn't pull an ounce of gold out of the ground, but he sold dry goods and, of course, well-made, reasonably priced denim overalls to the surging crowd of gold seekers hitting San Francisco at the time.
Today, Levi Strauss & Co. is a globally recognized brand (and a $4.5 billion company). You can't buy its stock, but I'm willing to bet you've bought more than a few pairs of jeans from Strauss' heirs.
In 2017, the profit potential in marijuana isn't much different… except for the fact that there's exponentially more money to be made.
Just like in the 19th century, 2017's "pick-and-shovel" cannabis plays will mint millionaires.
You can be one of them…
When Regulations Are Good for Stock Prices
Just a few weeks ago, I attended the fourth annual Cannabis Business Summit and Expo in Oakland, Calif., on the north end of Silicon Valley. I tend to think of "Oaksterdam" as the "spiritual home" of the legal weed movement because of the initial successes that legalization advocates and activists had there in forming California's long-established medical marijuana industry.
The hottest profit trend on display at the expo wasn't growers, or dispensers, or even edibles, but compliance.
You see, it varies from state to state, but the legal cannabis industry has voluntarily embraced some pretty stiff regulatory regimes, not only to satisfy opponents like weed "flat-earther" Jeff Sessions, our U.S. Attorney General, but also to ensure people are kept safe as they consume the product and to make sure everything is dealt aboveboard.
Regulation in this case is a boon for investors, because the regulations generate a very real need for other firms to come aboard and offer their expertise, by way of products and services, in a way that boosts bottom lines.
With regulations thick on the ground, you can see that compliance is critical. In some cases, a company that makes just one wrong compliance move can face severe legal sanctions that could damage its reputation and cripple the business, so there's a real incentive here for getting it right the first time.
Many pot entrepreneurs lack the knowledge and experience necessary to comply with all state and local regulations, from employment and labor laws to inventory control and everything in between.
We're talking about a market likely to top $35 billion in three years. The stakes are just too high to leave anything to chance.
Entrepreneurs are turning in droves to the one company that can make it all easy for them…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.